With respect to EGFR inhibitor-induced differential toxicity, a recent study of non-small cell lung cancer patients treated with erlotinib showed that only the large intestine exhibited signs of erlotinib-induced toxicity32. Here, EGFR is linked to non-small cell lung carcinoma.